The present study was undertaken to evaluate the effectiveness of ebastine (Ebastel®) in patients with Japanese cedar pollinosis, using the Japan rhino-conjunctivitis quality of life questionnaire (JRQLQ). The subjects of this study consisted of 524 patients who visited our hospitals and clinics during the peak pollen exposure season in 2004 (between March 1 and 14). After excluding any patients falling under the exclusion criteria, the patients who had taken ebastine once daily prior to entering this study were classified as the treated group, while the patients without any previous treatment were classified as the non-treated group. As a result, the treated-group consisted of 138 sub-jects while the Non-treated group comprised 198 in our analysis. Nasal and ocular symptoms (nasal discharge, sneezing, nasal congestion, nasal itching, ocular itching and lacrimal hypersecretion) were all significantly less severe in the treated group than in the non-treated group. Regarding the QOL (17 items), all items except for “difficulty in going out” were significantly more favorable during the peak pollen exposure season in the treated group than in the non-treated group. In analyzing the scores of each QOL category (daily living, outdoor activity, social activity, sleep, physical condition and mental condition), the score of each category was significantly better in the treated group than in the non-treated group. In addition, in an assessment using the facial scale (the total combined scores of the nasal symptoms, ocular symptoms and QOL), the score was also significantly better in the treated group. These results therefore showed that ebastine prophylactic treatment for Japanese cedar pollinosis resulted in a significant alleviation of the clinical symptoms and also demonstrated a significantly improvement in the patient QOL based on the findings of the JRQLQ.
View full abstract